Clinical trial participation and time to treatment among adolescents and young adults with cancer: does age at diagnosis or insurance make a difference?
- PMID: 21931022
- PMCID: PMC3209697
- DOI: 10.1200/JCO.2011.36.2954
Clinical trial participation and time to treatment among adolescents and young adults with cancer: does age at diagnosis or insurance make a difference?
Abstract
Purpose: Because adolescent and young adult (AYA) patients with cancer have experienced variable improvement in survival over the past two decades, enhancing the quality and timeliness of cancer care in this population has emerged as a priority area. To identify current trends in AYA care, we examined patterns of clinical trial participation, time to treatment, and provider characteristics in a population-based sample of AYA patients with cancer.
Methods: Using the National Cancer Institute Patterns of Care Study, we used multivariate logistic regression to evaluate demographic and provider characteristics associated with clinical trial enrollment and time to treatment among 1,358 AYA patients with cancer (age 15 to 39 years) identified through the Surveillance, Epidemiology, and End Results Program.
Results: In our study, 14% of patients age 15 to 39 years had enrolled onto a clinical trial; participation varied by type of cancer, with the highest participation in those diagnosed with acute lymphoblastic leukemia (37%) and sarcoma (32%). Multivariate analyses demonstrated that uninsured, older patients and those treated by nonpediatric oncologists were less likely to enroll onto clinical trials. Median time from pathologic confirmation to first treatment was 3 days, but this varied by race/ethnicity and cancer site. In multivariate analyses, advanced cancer stage and outpatient treatment alone were associated with longer time from pathologic confirmation to treatment.
Conclusion: Our study identified factors associated with low clinical trial participation in AYA patients with cancer. These findings support the continued need to improve access to clinical trials and innovative treatments for this population, which may ultimately translate into improved survival.
Conflict of interest statement
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
Similar articles
-
Increased clinical trial enrollment among adolescent and young adult cancer patients between 2006 and 2012-2013 in the United States.Pediatr Blood Cancer. 2019 Jan;66(1):e27426. doi: 10.1002/pbc.27426. Epub 2018 Sep 6. Pediatr Blood Cancer. 2019. PMID: 30256525 Free PMC article.
-
Adolescent and young adult enrollment to a National Cancer Institute-sponsored National Clinical Trials Network Research Group over 25 years.Cancer. 2021 Dec 15;127(24):4574-4584. doi: 10.1002/cncr.33855. Epub 2021 Aug 5. Cancer. 2021. PMID: 34351619 Free PMC article.
-
Use of appropriate initial treatment among adolescents and young adults with cancer.J Natl Cancer Inst. 2014 Oct 9;106(11):dju300. doi: 10.1093/jnci/dju300. Print 2014 Nov. J Natl Cancer Inst. 2014. PMID: 25301964 Free PMC article.
-
The challenges of clinical trials for adolescents and young adults with cancer.Pediatr Blood Cancer. 2008 May;50(5 Suppl):1101-4. doi: 10.1002/pbc.21459. Pediatr Blood Cancer. 2008. PMID: 18360838 Review.
-
Acute lymphoblastic leukemia in adolescents and young adults.Cancer. 2017 Jul 1;123(13):2398-2403. doi: 10.1002/cncr.30624. Epub 2017 Mar 22. Cancer. 2017. PMID: 28328172 Review.
Cited by
-
Assessing information and service needs of young adults with cancer at a single institution: the importance of information on cancer diagnosis, fertility preservation, diet, and exercise.Support Care Cancer. 2013 Sep;21(9):2477-84. doi: 10.1007/s00520-013-1809-4. Epub 2013 Apr 21. Support Care Cancer. 2013. PMID: 23604520
-
Controversies in the Treatment of Adolescents and Young Adults with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.Curr Oncol Rep. 2022 Aug;24(8):995-1001. doi: 10.1007/s11912-022-01276-2. Epub 2022 Mar 30. Curr Oncol Rep. 2022. PMID: 35353349 Review.
-
Understanding care and outcomes in adolescents and young adult with Cancer: A review of the AYA HOPE study.Pediatr Blood Cancer. 2019 Jan;66(1):e27486. doi: 10.1002/pbc.27486. Epub 2018 Oct 7. Pediatr Blood Cancer. 2019. PMID: 30294882 Free PMC article. Review.
-
Nonmetropolitan residence and other factors affecting clinical trial enrollment for adolescents and young adults with cancer in a US population-based study.Cancer. 2019 Jul 1;125(13):2283-2290. doi: 10.1002/cncr.32038. Epub 2019 Mar 22. Cancer. 2019. PMID: 30901085 Free PMC article.
-
Patient, Caregiver, and Clinician Perspectives on Core Components of Therapeutic Alliance for Adolescents and Young Adults With Advanced Cancer: A Qualitative Study.JAMA Netw Open. 2023 Aug 1;6(8):e2328153. doi: 10.1001/jamanetworkopen.2023.28153. JAMA Netw Open. 2023. PMID: 37556137 Free PMC article.
References
-
- Adolescent and Young Adult Oncology Progress Review Group. Bethesda, MD: National Institutes of Health; 2006. Closing the Gap: Research and Care Imperatives for Adolescents and Young Adults With Cancer.
-
- Bleyer A, O'Leary M, Barr R, et al. Bethesda, MD: National Institutes of Health; 2006. Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, Including SEER Incidence and Survival; pp. 1975–2000.
-
- Bleyer WA. Latest estimates of survival rates of the 24 most common cancers in adolescent and young adult Americans. JAYAO. 2011;1:37–42. - PubMed
-
- Bleyer A, Barr R. Cancer in young adults 20 to 39 years of age: Overview. Semin Oncol. 2009;36:194–206. - PubMed
-
- Heron M: Deaths: Leading Causes for 2006. Hyattsville, MD: National Center for Health Statistics; 2010.
Publication types
MeSH terms
Grants and funding
- N01-PC-35145/PC/NCI NIH HHS/United States
- N01-PC-54405/PC/NCI NIH HHS/United States
- N01-PC-35141/PC/NCI NIH HHS/United States
- N01-PC-35139/PC/NCI NIH HHS/United States
- N01-PC-544044/PC/NCI NIH HHS/United States
- N01-PC-35133/PC/NCI NIH HHS/United States
- N01PC35137/CA/NCI NIH HHS/United States
- N01PC35138/PC/NCI NIH HHS/United States
- N01PC54403/PC/NCI NIH HHS/United States
- N01-PC-54403/PC/NCI NIH HHS/United States
- N01PC54402/PC/NCI NIH HHS/United States
- N01PC35145/CA/NCI NIH HHS/United States
- N01PC35136/CA/NCI NIH HHS/United States
- N01PC35133/PC/NCI NIH HHS/United States
- N01-PC-35138/PC/NCI NIH HHS/United States
- N01-PC-35142/PC/NCI NIH HHS/United States
- N01PC35141/PC/NCI NIH HHS/United States
- N01PC35143/CA/NCI NIH HHS/United States
- N01-PC-35137/PC/NCI NIH HHS/United States
- N01PC54405/PC/NCI NIH HHS/United States
- N01-PC-35135/PC/NCI NIH HHS/United States
- N01PC35135/PC/NCI NIH HHS/United States
- N01PC35142/CA/NCI NIH HHS/United States
- N01PC54404/CA/NCI NIH HHS/United States
- N01PC35139/CA/NCI NIH HHS/United States
- N01-PC-54402/PC/NCI NIH HHS/United States
- N01-PC-35143/PC/NCI NIH HHS/United States
- N01-PC-35136/PC/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous